Global Idiopathic Pulmonary Fibrosis Competitive Landscape to 2026 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Idiopathic
Pulmonary Fibrosis: Competitive Landscape to 2026” report has
been added to ResearchAndMarkets.com’s offering.

“Idiopathic Pulmonary Fibrosis: Competitive Landscape to 2026”, uses
in-house analyst expertise to provide a competitive assessment of the
disease marketplace.

Idiopathic pulmonary fibrosis (IPF) is a progressive disease that
results in the scarring of lung tissue and changes the lung’s ability to
function normally. The most common signs and symptoms of idiopathic
pulmonary fibrosis are dyspnea and a persistent nonproductive cough.
Many affected individuals also experience a loss of appetite and gradual
weight loss. IPF primarily occurs in older adults. However, the causes
are unknown.

This report provides

• The IPF pipeline consists of 132 drugs spanning all stages of
  development with approximately two-third of the drugs in the
  preclinical stage. The strength of the IPF pipeline is strong with 14
  drugs, all with novel MOAs, in late-stage clinical development
• Close to 43% of IPF clinical trials have been conducted in North
  America between 2010-2017. 66 clinical trials were recorded in North
  America between 2010-2017Overall, IPF clinical trials have had
  relatively high enrollment efficiencies in all phases except for Phase
  III, which had close to 84% efficiency
• Phase II clinical trials had the highest enrollment efficiency (105%),
  which could be due to patients being more willing to participate due
  to increased confidence in the safety and efficacy of a late-stage drug

Scope

• Pipeline Assessment-regional breakdown, promising late-stage products,
  early-stage pipeline by molecule type
• Clinical Trials Assessment-trial breakdown by phase, leading industry
  and non-industry sponsors, enrollment analytics
• Commercial Assessment-leading marketed products, current and future
  players
• Competitive Landscape Analysis-key market events (2016-2026).

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies
  through a review of pipeline products and technologies, and by
  identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and
  driving the global IPF market.
• Drive revenues by understanding the key trends, innovative products
  and technologies, market segments, and companies likely to impact the
  global IPF market in the future.
• Formulate effective sales and marketing strategies by understanding
  the competitive landscape and by analyzing the performance of various
  competitors.
• Identify emerging players with potentially strong product portfolios
  and create effective counter-strategies to gain a competitive
  advantage.
• Organize your sales and marketing efforts by identifying the market
  categories and segments that present maximum opportunities for
  consolidations, investments, and strategic partnerships.

Key Topics Covered:

1. Preface

1.1 Abbreviations

1.2 Related Reports

2. Executive Summary

2.1 Key Findings

2.2 Key Events

3. Introduction

3.1 Report Scope

3.2 Disease Overview and Epidemiology

4. Pipeline Assessment

4.1 Pipeline Overview

4.2 Pipeline Breakdown by Region/Country

4.3 Pipeline Breakdown by Molecule Type and Target

4.4 Drug Review Designations

4.5 Products in Clinical Development

5. Clinical Trial Assessment

5.1 Clinical Trials Overview

5.2 Top Sponsors of Clinical Trials in IPF

5.3 Trial Breakdown by Region

5.4 Therapy Area Perspective

5.5 Enrollment Analytics

6 Commercial Assessment

6.1 Leading Marketed Products

6.2 Current & Future Players

7. Competitive Landscape Analysis (2016-2026)

7.1 Events Classification Overview

7.2 US

7.3 5EU

7.4 Japan

8 Appendix

Companies Mentioned

• Roche
• Boehringer Ingelheim
• Zambon
• Galapagos NV
• Prometic Life Sciences Inc
• Novartis
• Biogen
• Promedior
• FibroGen

For more information about this report visit https://www.researchandmarkets.com/r/ci7nhb

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Respiratory
Drugs